• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

ChromoTek PD-L1 VHH, recombinant binding protein for 2x Cys conjugation

Alpaca anti-PD-L1 VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.

Host/Type

Alpaca VHH

Reactivity

Human

Applications

Conjugation

Conjugate

Unconjugated

Cat No : pdloCys2

Synonyms

PD-L1-Nanobody, PD-L1-Single domain antibody (sdAb), B7 homolog 1, B7-H1, CD274, programmed cell death 1 ligand 1, PDL1, PD-L1

Validation Data Gallery

  • The affinity of anti-human PD-L1 recombinant VHH towards human PD-L1 was determined using biolayer interferometry (BLI). Biotinylated, recombinant human PD-L1 was immobilized on Streptavidin biosensors and assayed with 0.4 to 25 nM of FITC Plus conjugated-PD-L1 VHH (FITC-pdlo). Fit indicates a 1:1 binding model fitted to the data.

    The affinity of anti-human PD-L1 recombinant VHH towards human PD-L1 was determined using biolayer interferometry (BLI). Biotinylated, recombinant human PD-L1 was immobilized on Streptavidin biosensors and assayed with 0.4 to 25 nM of FITC Plus conjugated-PD-L1 VHH (FITC-pdlo). Fit indicates a 1:1 binding model fitted to the data.

Product Information

Alpaca anti-PD-L1 VHH, purified recombinant binding protein. Suitable for for cysteine conjugation with thiol-reactive reagents, e.g. maleimides. Note: unconjugated VHHs are not suited for usage without prior labeling, since they contain reactive Cysteines. Shipment and storage buffers contain TCEP to keep Cysteins reduced.

ApplicationsConjugation
ReactivityHuman
ConjugateUnconjugated
TypeNanobody
ClassRecombinant
HostAlpaca
AffinityPicomolar range, below the assay limit (biolayer interferometry)
Molecular Weight13.887 kDa
FormLiquid
RRIDAB_3661833
Storage Buffer10 mM HEPES, 500 mM NaCl, pH 7.0, 1 mM TCEP, 0.09% sodium azide
Storage ConditionStore at -20°C
BackgroundPD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. D-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681).

Documentation

SDS
SDS-Immuno-Oncology VHHs